Design of a Phase 2 Study to Evaluate Fosmanogepix (APX001), a novel antifungal, for the Treatment of Patients with Invasive Mold Infections (IMI) with limited treatment options
Design of a Phase 2 Study to Evaluate Fosmanogepix (APX001), a novel antifungal, for the Treatment of Patients with Invasive Mold Infections (IMI) with limited treatment optionsConference abstracts
Source: The Aspergillus Website - updates - Category: Respiratory Medicine Authors: Jackie Salisbury Source Type: news